A5044208961- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pulmonary Hypertension Research and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Medical Imaging and Pathology Studies
- Cystic Fibrosis Research Advances
- Occupational and environmental lung diseases
- Systemic Sclerosis and Related Diseases
- Eosinophilic Disorders and Syndromes
- Respiratory and Cough-Related Research
- Neonatal Respiratory Health Research
- Dysphagia Assessment and Management
- Inflammatory Myopathies and Dermatomyositis
- Lung Cancer Diagnosis and Treatment
- Occupational exposure and asthma
- Tracheal and airway disorders
- Gastroesophageal reflux and treatments
- COVID-19 and healthcare impacts
- Respiratory Support and Mechanisms
- Venous Thromboembolism Diagnosis and Management
- COVID-19 Clinical Research Studies
- Transplantation: Methods and Outcomes
- Cardiac tumors and thrombi
- Esophageal Cancer Research and Treatment
- Vascular Anomalies and Treatments
Royal Prince Alfred Hospital
2016-2025
The University of Sydney
2016-2025
Chungbuk National University
2025
Sunnybrook Health Science Centre
2024
Health Sciences Centre
2024
Cooperative Trials Group for Neuro-Oncology
2020-2022
National Health and Medical Research Council
2018-2022
Concord Repatriation General Hospital
2013
Nepean Hospital
2013
The prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease, is estimated at 1.25–63 out 100 000, making large population studies difficult. Recently, the need for longitudinal registries to study IPF has been recognised. Australian Registry (AIPFR) national registry collating comprehensive data patients across Australia. We explored characteristics this cohort effect demographic physiological parameters specific management on mortality. Participants in AIPFR...
Rationale: Reliable outcome prediction in patients with fibrotic lung disease using baseline high-resolution computed tomography (HRCT) data remains challenging. Objectives: To evaluate the prognostic accuracy of a deep learning algorithm (SOFIA [Systematic Objective Fibrotic Imaging Analysis Algorithm]), trained and validated identification usual interstitial pneumonia (UIP)-like features on HRCT (UIP probability), large cohort well-characterized progressive drawn from national registry....
Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia New Zealand (TSANZ) Lung Foundation (LFA) published position statement on treatment IPF. Since that time, subsidized anti‐fibrotic therapy in form pirfenidone nintedanib now available both Zealand. More recently, evidence has been support for non‐IPF (PPF). Additionally, there have numerous publications relating non‐pharmacologic...
Multidisciplinary discussions (MDDs) have been shown to improve diagnostic accuracy in interstitial lung disease (ILD) diagnosis. However, their clinical impact on patient care has never clearly demonstrated. We describe the effect that an ILD multidisciplinary service upon diagnosis and management of patients with suspected ILD.Patients at two specialized centres underwent team review (ILD-MDT) (standard clinic visit ILD-MDD). compared changes referral those following ILD-MDT.Ninety...
ABSTRACT Pulmonary complications in CTD are common and can involve the interstitium, airways, pleura pulmonary vasculature. ILD occur all (CTD‐ILD), may vary from limited, non‐progressive lung involvement, to fulminant, life‐threatening disease. Given potential for major adverse outcomes CTD‐ILD, accurate diagnosis, assessment careful consideration of therapeutic intervention a priority. Limited data available guide management decisions CTD‐ILD. Autoimmune‐mediated inflammation is considered...
Background Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which circulatory biomarkers have the potential for guiding management clinical practice. We assessed prognostic role of serum three independent IPF cohorts: Australian Pulmonary Fibrosis Registry (AIPFR), Trent Lung (TLF) and Prospective Observation Clinical Endpoints (PROFILE). Methods In AIPFR cohort, candidate proteins were by ELISA as well an unbiased proteomic approach. LASSO (least absolute shrinkage...
Abstract Background and objective Prediction of disease course in patients with progressive pulmonary fibrosis remains challenging. The purpose this study was to assess the prognostic value lung extent quantified at computed tomography (CT) using data‐driven texture analysis (DTA) a large cohort well‐characterized idiopathic (IPF) enrolled national registry. Methods This retrospective included participants Australian IPF Registry available CT between 2007 2016. scans were analysed DTA method...
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung disease of unknown cause. The advent anti-fibrotic medications known to slow progression has revolutionised IPF management in recent years. However, little about the natural history patients with mild physiological impairment. We aimed assess these using data from Australian Registry (AIPFR). Using our cohort real-world patients, we compared FVC criteria for impairment (FVC ≥ 80%) against other proposed criteria:...
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with poor prognosis. Antifibrotics slow the decline of function after 12-months, but limited studies have examined role circulatory biomarkers in antifibrotic treated IPF patients. Serum from 98 participants, Australian Pulmonary Fibrosis Registry were collected at four time-points over 1 year post-antifibrotic treatment and analysed as two separate cohorts. Patients stratified progressive, if they experienced ≥ 10%...
Multidisciplinary meetings (MDM) are the current "gold standard" in interstitial lung disease (ILD) diagnosis and comprise inter-disciplinary discussion of multiple forms information to provide diagnostic management outputs. Although bias could be potentially inserted at any step process, date there has been no consensus regarding appropriate constitution governance MDM. We sought determine features ILD MDMs based within centres excellence around world.An internet questionnaire was sent...
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease (ILD) of unknown aetiology with median survival only 2-5 years. It characterized by progressive dyspnoea and worsening function, ultimately resulting in death. Until recently, there were no effective therapies for IPF; however, the publication two landmark clinical trials 2014, anti-fibrotic therapies, nintedanib pirfenidone, have gained widespread approval. This position paper aims to highlight current evidence...
Idiopathic pulmonary fibrosis (IPF) with coexistent emphysema, termed combined and emphysema (CPFE) may associate reduced forced vital capacity (FVC) declines compared to non-CPFE IPF patients. We examined associations between mortality functional measures of disease progression in two cohorts.
Gastroesophageal reflux disease (GORD) is highly prevalent in idiopathic pulmonary fibrosis (IPF) and may play a role its pathogenesis. Recent IPF treatment guidelines suggest that all patients with be considered for antacid therapy. However, emerging evidence suggests therapy does not improve patient outcomes increase the risk of infection. Using prospectively collected data from Australian Registry including use therapy, GORD diagnosis symptoms, relationship these variables to survival...
<b>Blood monocytes have been recently proposed as a potential prognostic marker for IPF. Data from the Australian IPF registry shown that elevated monocytes, neutrophils and total leukocytes significantly predict poorer survival in patients.</b>http://bit.ly/38GP7f0
Rationale: The interstitial lung disease (ILD) multidisciplinary meetings (MDM), composed of pulmonologists, radiologists, and pathologists, is integral to the rendering an accurate ILD diagnosis. However, there significant heterogeneity in conduct MDMs, questions regarding their best practices remain unanswered. Objectives: To achieve consensus among experts on essential components MDM. Methods: Using a Delphi methodology, semi-structured interviews with were used identify key themes...
Abstract The role of non‐invasive ventilation (NIV) in patients with cystic fibrosis (pwCF) includes use both the management hypercapnic respiratory failure and as an adjunct to airway clearance techniques. We performed a retrospective review Australian Cystic Fibrosis Data Registry analyse characteristics pwCF requiring NIV. demonstrated that despite improvements overall health there is still significant NIV this population.
ABSTRACT Background and objective Current guidelines for the diagnosis of idiopathic pulmonary fibrosis (IPF) provide specific criteria in setting multidisciplinary discussion (MDD). We evaluate utility reproducibility these diagnostic guidelines, using clinical data from Australian IPF Registry. Methods All patients enrolled registry undergo a review whereby international are applied via MDD. investigated applicability with regard to: (i) adherence to (ii) Natural history categories (iii)...
Interstitial Lung Disease (ILD) is a group of respiratory conditions affecting the lung interstitium often associated with progressive failure. There increasing recognition need for improved epidemiological data to help determine best practice and improve standardisation care. The Australasian ILD Registry (AILDR) bi-national registry patients all subtypes designed establish clinically meaningful database reflecting real world in Australasia an objective diagnostic treatment pathways through...